|Bid||3.6000 x 1800|
|Ask||4.0300 x 800|
|Day's Range||3.8650 - 4.0700|
|52 Week Range||2.6000 - 14.3500|
|Beta (3Y Monthly)||0.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019 - Nov 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.50|
Bain Capital Life Sciences Managing Director brings extensive capital markets and diverse life sciences industry experience EMERYVILLE, Calif., Aug. 12, 2019 -- Dynavax.
EMERYVILLE, Calif., Aug. 08, 2019 -- Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and.
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -4.76% and 4.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies Corporation (DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other conditions, an aggregate of up to $60.0 million of shares of its common stock, shares of newly designated non-voting Series B Convertible Preferred Stock and warrants to purchase common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cowen and William Blair are acting as joint book-running managers for the offering.
Second quarter 2019 HEPLISAV-B® net product revenue of $8.3 millionUpdated net product revenue guidance of $32-$36 million for full year 2019Conference call to be held today at.
BERKELEY, Calif., July 24, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on developing novel vaccines, will.
Is Dynavax Technologies Corporation (NASDAQ:DVAX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]
BERKELEY, Calif., June 03, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim.
Progression Free Survival (PFS) rate of 18-months in 72% of patientsClinical efficacy in patients with immunologically cold tumor at baselineThe combination of SD-101 and.
24% overall response rate in ITT populationResponses were observed in SD-101 injected and non-injected lesions The combination of SD-101 and pembrolizumab was well-tolerated.
After two successive weeks of losses, biotech stocks slowly clawed back. Multiple conference presentations, independent clinical trial readouts and a few FDA decisions marked the key events in the biotech ...
The company is returning its focus to its easier-to-take hepatitis B vaccine and other vaccine work.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
Dynavax Technologies Corp. said late Thursday it will focus on its vaccine business and on its first commercial product, a hepatitis B vaccine, looking to unwind its immuno-oncology business. The company will also lay off workers and trim operations to focus on the vaccine's commercialization. "Following a comprehensive analysis of our assets, strengths and opportunities, we have determined we should focus our resources on our approved vaccine, HEPLISAV-B, which, as the only two-dose hepatitis B vaccine, is gaining market share and is well positioned to become the new standard of care in the U.S," Chief Executive Eddie Gray said. In the same press release, Gray said that the restructuring was "the optimal time" for his retirement, effective Aug. 1. The company's board of directors has created an interim office of the president and has appointed David Novack and Ryan Spencer, two senior vice presidents, as co-presidents effective immediately. Shares of Dynavax, halted earlier in the extended session, fell more than 5% when they resumed trading. The shares ended the regular session 0.2% lower.
Dynavax Technologies Corporation (DVAX), today announced a strategic restructuring to prioritize its vaccine business by focusing on the company’s first commercial product HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]. As part of the restructuring, the company will explore strategic alternatives for its immuno-oncology portfolio and will reduce the company’s workforce and operations to focus resources on HEPLISAV-B commercialization.